Patient characteristics
Patients were assessed for eligibility between March 2018 and April 2019 across seven sites in the USA. Enrollment was completed in April 2019 and follow-up of the study remains ongoing. As of 29 April 2020 (analysis cutoff date), 49 patients overall were randomized before surgery. Patients in cohort 1 were randomized in a 2:2:1 ratio to ivosidenib 500 mg q.d., vorasidenib 50 mg q.d. or no treatment before surgery. After documenting inhibition of the m